UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                   FORM 10-QSB

             [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                      THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2006

                                       Or

 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

 For the transition period from _____________ __, ____ to _____________ __, ____

                        Commission File Number: 000-30191

                       KRONOS ADVANCED TECHNOLOGIES, INC.

             (Exact name of registrant as specified in its charter)


                   Nevada                               87-0440410
        (State or other jurisdiction of              (I.R.S. Employer
        incorporation or organization)              Identification No.)


            494 Common Street, Suite 301, Belmont, MA          02478
         (Address of principal executive offices)            (Zip Code)

                                 (617) 993-9965
              (Registrant's telephone number, including area code)



  -------------------------------------------------------------------------
 (Former name, former address and former fiscal year, if changed since last
  report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
                                                                 X Yes    __No

Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one):

Large accelerated filer ___   Accelerated filer ___    Non-accelerated filer X

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).
                                                                 __ Yes    X No

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date. As of May 12, 2006, there were
122,863,416 shares outstanding of the issuer's common stock.

<PAGE>

                                     PART I

FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The following comprise our (unaudited) consolidated financial statements for the
three and nine months ended March 31, 2006.


                       KRONOS ADVANCED TECHNOLOGIES, INC.
                           CONSOLIDATED BALANCE SHEETS



                                             March 31,
                                               2006                 June 30,
Assets                                     (Unaudited)                2005
                                         ----------------       ----------------
Current Assets
 Cash                                    $       469,320        $     1,554,906
 Prepaids                                        103,388                263,490
                                         ----------------       ----------------
  Total Current Assets                           572,708              1,818,396
                                         ----------------       ----------------
Net Property and Equipment                         2,026                  2,627

Other Assets
 Intangibles                                   2,016,975              2,138,814
                                         ----------------       ----------------
  Total Other Assets                           2,016,975              2,138,814
                                         ----------------       ----------------
Total Assets                             $     2,591,709        $     3,959,837
                                         ================       ================

Liabilities and Stockholders' Deficit

Current Liabilities
 Accrued expenses and payables
  to directors and officers              $        69,372        $        28,837
 Accounts payable                                169,436                479,175
 Accrued expenses                                845,155                487,070
 Notes payable, current portion                2,240,000              4,028,131
 Notes payable to directors and
  officers                                       242,353                397,004
                                         ----------------       ----------------
  Total Current Liabilities                    3,566,316              5,420,217
                                         ----------------       ----------------
Long Term Liabilities
  Notes payable                                2,575,000              2,400,000
                                         ----------------      -----------------
  Total Long Term Liabilities                  2,575,000              2,400,000
                                         ----------------      -----------------

     Total Liabilities                         6,141,316              7,820,217
                                         ----------------      -----------------
Stockholders' Deficit
 Common stock, authorized
 500,000,000 shares of $0.001 par value
 Issued and outstanding - 116,904,499
 and 72,686,345, respectively                    116,904                 72,686
Capital in excess of par value                26,078,818             23,183,747
Accumulated deficit                          (29,745,329)           (27,116,813)
                                         ----------------       ----------------
  Total Stockholders' Deficit                 (3,549,607)            (3,860,380)
                                         ----------------       ----------------
  Total Liabilities and
   Stockholders' Deficit                 $     2,591,709         $    3,959,837
                                         ================       ================



The accompanying notes are an integral part of these financial statements.

<PAGE>

                       KRONOS ADVANCED TECHNOLOGIES, INC.
                      CONSOLIDATED STATEMENTS OF OPERATIONS



<TABLE>
<CAPTION>

                                   Three months ended March 31,       Nine months ended March 31,
                                 -------------------------------     ------------------------------
                                    2006               2005              2006             2005
                                 ------------       ------------     ------------      ------------
                                 (Unaudited)         (Unaudited)      (Unaudited)       (Unaudited)
<S>                              <C>                <C>              <C>               <C>
Sales                            $      -           $    48,928      $    37,500       $   430,379

Cost of sales                           -                41,549            8,449           375,397
                                 ------------       ------------     ------------      ------------
Gross Profit                            -                 7,379           29,051            54,982
                                 ------------       ------------     ------------      ------------

Selling, General and
 Administrative expenses
  Compensation and benefits          292,043            371,413          821,544           889,415
  Research and development            92,726             23,642          232,652            78,207
  Professional services              134,563            108,176          236,812            95,119
  Depreciation and amortization      133,861             98,931          473,451           297,206
  Insurance                           37,144             46,120          111,432           138,361
  Facilities                          22,429             23,859           69,024            67,792
  Other                               88,792             26,414          288,622           166,356
                                 ------------       ------------     ------------      ------------
 Selling, General and
  Administrative expenses            801,558            698,555        2,233,537         1,732,456
                                 ------------       ------------     ------------      ------------

Net Operating Loss                  (801,558)          (691,176)      (2,204,486)       (1,677,474)

Loss on Debt Restructuring              -                  -                -           (3,857,467)
Other Income                            -                 1,012             -                1,415
Interest Expense                    (120,956)          (117,168)        (424,030)         (411,324)
                                 ------------       ------------     ------------      ------------

Net Loss                         $  (922,514)       $  (807,332)     $(2,628,516)      $(5,944,850)
                                 ============       ============     ============      ============

Net Loss Per Share
 - Basic and diluted             $     (0.01)       $     (0.01)     $     (0.03)      $     (0.09)
                                 ============       ============     ============      ============

Weighted average
 shares outstanding
 - Basic and diluted             107,372,928         71,578,502       88,245,584        67,612,904
                                 ============       ============     ============      ============
</TABLE>



The accompanying notes are an integral part of these financial statements.

<PAGE>

                       KRONOS ADVANCED TECHNOLOGIES, INC.
                      CONSOLIDATED STATEMENTS OF CASH FLOWS



                                         For the nine months ended March 31,
                                         -----------------------------------
                                              2006               2005
                                           ------------       -------------
                                           (Unaudited)        (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
 Net loss from operations                  $(2,628,516)       $ (5,944,850)
 Adjustments to reconcile net loss to
 net cash used in operations
  Depreciation and amortization                473,451             297,206
  Stock options granted for
   compensation/services                        79,290                -
  Accretion of note discount                      -                 92,965
  Loss on debt restructuring                      -              3,857,467
 Change In
  Accounts receivable                             -                 48,615
  Prepaid expenses and other assets              3,227              60,685
  Deferred revenue                                -                 (3,218)
  Accounts payable                            (269,204)           (193,863)
  Accrued expenses and other liabilities       358,085             126,599
                                           ------------       -------------
    Net cash Used in Operations             (1,983,667)         (1,658,394)

CASH FLOWS FROM INVESTING ACTIVITIES
 Purchases on property & equipment              (2,100)               -
 Investment in patent protection              (172,036)            (54,134)
                                           ------------       -------------
Net cash Used in Investing Activities         (174,136)            (54,134)
                                           ------------       -------------

CASH FLOWS FROM FINANCING ACTIVITIES
 Issuance of common stock                    2,860,000           1,030,000
 Proceeds from short-term borrowings              -                100,000
 Repayments of short-term borrowings        (1,942,783)         (1,086,261)
 Proceeds from long-term borrowings            175,000           4,400,000
 Repayments from long-term borrowings             -             (2,400,000)
 Debt acquisition costs                        (20,000)           (212,500)
                                           ------------       -------------
Net cash Provided by Financing
 Activities                                  1,072,217           1,831,239
                                           ------------       -------------
NET (DECREASE) INCREASE IN CASH             (1,085,586)            118,711

CASH
 Beginning of period                         1,554,906              69,063
                                           ------------       -------------
 End of period                             $   469,320        $    187,774
                                           ============       =============
Supplemental schedule of non-cash
investing and financing activities:

Interest paid in cash                      $      -           $    111,359
                                           ============       =============

The accompanying notes are an integral part of these financial statements.

<PAGE>

                       KRONOS ADVANCED TECHNOLOGIES, INC.
               NOTES TO CONSOLIDATED INTERIM FINANCIAL STATEMENTS
                                   (UNAUDITED)

NOTE 1 - BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements of Kronos Advanced
Technologies, Inc. (the "Company") have been prepared in accordance with
generally accepted accounting principles for interim financial information.
Accordingly, they do not include all the information and notes required by
generally accepted accounting principles for complete financial statements. In
the opinion of management, all adjustments necessary to present fairly the
information set forth therein have been included. Operating results for the
three and nine months ended March 31, 2006 are not necessarily indicative of the
results that may be experienced for the fiscal year ending June 30, 2006.

These consolidated financial statements are those of the Company and its
wholly-owned subsidiary. All significant inter-company accounts and transactions
have been eliminated in the preparation of the consolidated financial
statements.

The accompanying consolidated financial statements should be read in conjunction
with the Kronos Advanced Technologies, Inc. Form 10-KSB for the fiscal year
ended June 30, 2005, which was filed on September 28, 2005.

NOTE 2 - REALIZATION OF ASSETS AND GOING CONCERN

The accompanying consolidated financial statements have been prepared in
conformity with accounting principles generally accepted in the United States of
America, which contemplate continuation of the Company as a going concern. The
Company has sustained losses from operations in recent years, and such losses
have continued through the nine months ended March 31, 2006. In addition, the
Company has used cash in rather than provided cash through its operations. The
Company is currently using its resources to attempt to raise capital necessary
to commercialize its technology and develop viable commercial products, and to
provide for its working capital needs.

In view of the matters described in the preceding paragraph, recoverability of a
major portion of the asset amounts shown in the accompanying balance sheet is
dependent upon the continued operations of the Company, which in turn is
dependent upon the Company's ability to meet its financing requirements on a
continuing basis, to maintain present financing and to succeed in its future
operations. The consolidated financial statements do not include any adjustments
relating to the recoverability and classification of recorded asset amounts or
amounts and classification of liabilities that might be necessary should the
Company be unable to continue in existence.

Management has taken the following steps with respect to its operating and
financial requirements, which it believes are sufficient to provide the Company
with the ability to continue in existence:

EOL. In December 2005, Kronos executed a non-exclusive License Agreement with
EOL, LLC, a Russian Federation corporation. Based in Korolev, Moscow Region,
Russia, EOL will leverage the Kronos technology to produce, market, and
distribute Kronos commercial air purification products, bacteriological and
virus destruction devices and space heaters in select Commonwealth of
Independent States. The agreement comes after successful completion of multiple
tests in Eastern Europe, which found the Kronos technology capable of
decontaminating rooms infected with airborne viruses and bacteria. Under the
terms of the five-year agreement, EOL will provide Kronos a fixed percentage
royalty on every product sold, as well as upfront licensing and quarterly
maintenance fees. Based on contractual milestones, EOL is required to: (i)
complete initial product design by March 2006; (ii) complete initial product
prototypes by June 2006; and (iii) make product available for customer purchase
by September 2006. EOL plans to assemble the finished products in Russia from
components supplied both locally and from contract manufacturers in China. The
products will be marketed and distributed in Russia, Ukraine, Kazakhstan,
Moldova and Byelorussia. In March 2006, EOL achieved the first milestone:
initial design of a wall mounted air sterilizer for the health care market.

HoMedics. October 2002, Kronos and HoMedics executed a Licensing Agreement
granting HoMedics certain rights with respect to the distribution of the Kronos
proprietary technology to the consumer. The agreement provides for exclusive
North American, Australian and New Zealand retail distribution rights for next
generation consumer air movement and purification products based on the patented
Kronos technology. The initial term of the agreement is three and one half years
from the initial sale of consumer air purification products by HoMedics, which
shall be no later than December 31, 2006, with the option to extend the
Licensing Agreement for six additional years. Kronos was compensated through an
initial royalty payment and will receive ongoing quarterly royalty payments
based on a percentage of sales. HoMedics will pay minimum royalty payments of at
least $2 million during the initial three and a half year term and on-going
royalty payments to extend the agreement. Kronos will retain the rights to all
of its intellectual property. HoMedics commitment includes funding a marketing
and advertising campaign to promote the Kronos-based product line. The products
will be distributed by HoMedics. HoMedics currently distributes their products
through major domestic retailers, including Wal-Mart, Home Depot, Sears, Bed
Bath & Beyond, and Linens 'N Things.

<PAGE>

We believe the Company has successfully completed the development of a
Kronos-based consumer standalone air purifier that is an efficient, high quality
product which is cost effective and easy to operate. In March 2005, Kronos and
HoMedics began expanding production development beyond the initial prototypes
and initiated increased product testing to complete the product claims platform.
In March and April 2005, Kronos modified the HoMedics design and ordered
prototype production devices from Kronos' preferred vendors along with select
components from a HoMedics preferred vendor. In August 2005, Kronos received
initial shipment of products from its low cost, contract manufacturer in Mexico
and China. In October 2005, Kronos completed internal testing of these products
under a testing protocol co-developed by Kronos and HoMedics. In December 2005,
HoMedics funded the Company a further $175,000 upon acceptance of Kronos testing
results. In January 2006, HoMedics agreed to fund any further efforts required
by Kronos in support of HoMedics effort to bring the consumer standalone air
purifier to market.

Other Consumer Applications. During the quarter ended March 31, 2006, several
leading global home appliance manufacturers initiated discussions with Kronos
with an interest in using the Kronos technology for developing select consumer
applications, including silent kitchen range hoods and vaporizers. With specific
customer input, Kronos is designing and developing prototypes for additional
customer demonstration and evaluation.

U.S. Navy. In November 2002, the U. S. Navy awarded Kronos a Small Business
Innovation Research Phase II contract worth $580,000. The Phase II contract
(commercialization phase) is an extension of the Phase I and the Phase I Option
work that began in 2001. It is intended that the Kronos devices developed under
this contract will be embedded in existing HVAC systems in order to move air
more efficiently than traditional, fan-based technology. In May 2005, Kronos
shipped the Kronos device to Northrop Grumman for testing and evaluation. Based
on the success of these initial tests, Northrop Grumman requested additional
modifications and improvements to the device. Northrop Grumman is scheduling
further testing.

Leading Business Jet Manufacturer. In January 2003, Kronos executed a
Development and Acquisition Agreement with a premier business jet manufacturer.
The agreement was the direct result of initial prototype development work
performed by the Kronos Research Team with input from the customer in 2002. The
Kronos devices being designed and manufactured under this contract will need to
meet all FAA safety standards, including environmental, flammability and
electromagnetic interference (EMI). The Company has completed product design and
development based on the customer's specific product application requirements.
We have completed testing and prepared for shipment the prototype product. We
are waiting for shipment instructions from the customer.

FAA Airline Cabin Environment Research Center of Excellence. In April 2006,
Kronos was invited to serve as a member and an industrial partner in the Federal
Aviation Administration's (FAA) Air Transportation Airliner Cabin Environment
Research Center of Excellence (ACER CoE). In this capacity, Kronos will provide
its real-time decontamination, air filtration, purification and technology
expertise to evaluate and develop solutions that proactively address and improve
cabin air quality. The program, led by the FAA, includes senior executives from
aerospace equipment manufacturers and leading American universities.

Leading Automotive Manufacturer. In August 2005, Kronos extended its work into
the transportation industry by signing a Prototype Development and Evaluation
Agreement with a leading luxury automotive manufacturer. The Kronos product has
been designed and produced to meet exacting customer standards for placement
inside of automobile passenger cabins. We have completed initial customer
specified testing. Based on successful testing with the customer, Kronos and the
customer are preparing further testing protocols for the product. Based on
additional product testing conducted at the customer's European facilities, the
customer is assessing alternative applications for the Kronos technology.

Washington Technology Center. In December 2004, Kronos and the University of
Washington were awarded funding for a research and technology development
project entitled "Heat Transfer Technology for Microelectronics and MEMS" by the
Washington Technology Center ("WTC"). The objective of the project is to develop
a novel energy-efficient heat transfer technology for cooling microelectronics.
Thermal management for microelectronics and MEMS systems is a challenge.
Existing cooling devices aren't meeting increasing needs for energy consumption
and heat dissipation. Kronos air handling technology is an emerging technology
that uses an electric field to exert force on ionized gas. Kronos is attempting
to develop an improved microchip air handling system that is smaller in size,
has high speed airflow, allows more targeted delivery of cooling to areas of
highest heat and is compatible with current processes. WTC will contribute
$40,000 to the project, with Kronos contributing $8,000, plus $32,000 in in-kind
services, including use of the Kronos Research and Product Development Facility.
In January 2006, Kronos and the University of Washington conducted a successful
bench scale demonstration of micron cooling of a MEMS chip.

<PAGE>

NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Method. The Company's consolidated financial statements are prepared
using the accrual method of accounting. The Company has elected a June 30 fiscal
year end.

Principles of Consolidation. The consolidated financial statements of the
Company include those of the Company and its subsidiary for the periods in which
the subsidiary was owned/held by the Company. All significant intercompany
accounts and transactions have been eliminated in the preparation of the
consolidated financial statements. At March 31, 2006, we had only one
subsidiary, Kronos Air Technologies, Inc.

Use of Estimates. The preparation of consolidated financial statements in
conformity with accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the dates of the financial statements and the reported
amounts of revenues and expenses during the periods. Actual results could differ
from those estimates.

Concentrations of Credit Risk. Financial instruments which can potentially
subject the Company to concentrations of credit risk consist principally of
trade receivables. The Company manages its exposure to risk through ongoing
credit evaluations of its customers and generally does not require collateral.
If necessary, the Company maintains an allowance for doubtful accounts for
potential losses and does not believe it is exposed to concentrations of credit
risk that are likely to have a material adverse impact on the Company's
financial position or results of operations.

Cash and Cash Equivalents. The Company considers all highly liquid short-term
investments, with a remaining maturity of three months or less when purchased,
to be cash equivalents. The Company maintains cash and cash equivalents with
high-credit, quality financial institutions. At March 31, 2006 the cash balances
held at financial institutions were in excess of federally insured limits.

Accounts Receivable. The Company provides an allowance for potential losses, if
necessary, on trade receivables based on a review of the current status of
existing receivables and management's evaluation of periodic aging of accounts.
Accounts receivable are shown net of allowances for doubtful accounts of $0 at
March 31, 2006 and June 30, 2005. The Company charges off accounts receivable
against the allowance for losses when an account is deemed to be uncollectible.

Property and Equipment. Property and equipment are recorded at cost.
Depreciation is provided over the estimated useful lives of the assets, which
range from three to seven years. Expenditures for major renewals and betterments
that extend the original estimated economic useful lives of the applicable
assets are capitalized. Expenditures for normal repairs and maintenance are
charged to expense as incurred. The cost and related accumulated depreciation of
assets sold or otherwise disposed of are removed from the accounts, and any gain
or loss is included in operations.

Intangibles. The Company uses assumptions in establishing the carrying value,
fair value and estimated lives of our long-lived assets and goodwill. The
criteria used for these evaluations include management's estimate of the asset's
continuing ability to generate positive income from operations and positive cash
flow in future periods compared to the carrying value of the asset, the
strategic significance of any identifiable intangible asset in our business
objectives, as well as the market capitalization of the Company. Cash flow
projections used for recoverability and impairment analysis use the same key
assumptions and are consistent with projections used for internal budgeting, and
for lenders and other third parties. If assets are considered to be impaired,
the impairment recognized is the amount by which the carrying value of the
assets exceeds the fair value of the assets. Useful lives and related
amortization or depreciation expense are based on our estimate of the period
that the assets will generate revenues or otherwise be used by Kronos. Factors
that would influence the likelihood of a material change in our reported results
include significant changes in the asset's ability to generate positive cash
flow, loss of legal ownership or title to the asset, a significant decline in
the economic and competitive environment on which the asset depends, significant
changes in our strategic business objectives, and utilization of the asset.

Income Taxes. Income taxes are accounted for in accordance with the provisions
of Statement of Financial Accounting Standards ("SFAS") No. 109. Deferred tax
assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date. Valuation allowances are established, when necessary, to reduce
deferred tax assets to the amounts expected to be realized, but no less than
quarterly.

<PAGE>

Research and Development Expenses. Costs related to research and development are
charged to research and development expense as incurred.

Net Loss Per Share. Basic loss per share is computed using the weighted average
number of shares outstanding. Diluted loss per share is computed using the
weighted average number of shares outstanding adjusted for the incremental
shares attributed to outstanding options and warrants to purchase common stock,
when their effect is dilutive.

Revenue Recognition. The Company recognizes revenue in accordance with Staff
Accounting Bulletin (SAB) 104, which requires evidence of an agreement, delivery
of the product or services at a fixed or determinable price, and assurance of
collection within a reasonable period of time. Further, Kronos Air Technologies
recognizes revenue on the sale of the custom-designed contract sales under the
percentage-of-completion method of accounting in the ratio that costs incurred
to date bear to estimated total costs. For uncompleted contracts where costs and
estimated profits exceed billings, the net amount is included as an asset in the
balance sheet. For uncompleted contracts where billings exceed costs and
estimated profits, the net amount is included as a liability in the balance
sheet. Sales are reported net of applicable cash discounts and allowances for
returns. Revenue from government grants for research and development purposes is
recognized as revenue as long as the Company determines that the government will
not be the sole or principal expected ultimate customer for the research and
development activity or the products resulting from the research and development
activity. Otherwise, such revenue is recorded as an offset to research and
development expenses in accordance with the Audit and Accounting Guide, Audits
of Federal Government Contractors. In either case, the revenue or expense offset
is not recognized until the grant funding is invoiced and any customer
acceptance provisions are met or lapse.

Stock, Options and Warrants Issued for Services. Issuances of shares of the
Company's stock to employees or third-parties for compensation or services is
valued using the closing market price on the date of grant for employees and the
date services are completed for non-employees. Issuances of options and warrants
of the Companies stock are valued using the Black-Scholes option model.

Stock Options. In December 2004, the Financial Accounting Standards Board
("FASB") issued Statement of Financial Accounting Standards No. 123R,
Share-Based Payment ("SFAS No. 123R"). This Statement is a revision of SFAS No.
123, Accounting for Stock-Based Compensation, and supersedes Accounting
Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and
its related implementation guidance. SFAS No. 123R focuses primarily on
accounting for transactions in which an entity obtains employee services in
share-based payment transactions. The Statement requires entities to recognize
stock compensation expense for awards of equity instruments to employees based
on the grant-date fair value of those awards (with limited exceptions). Kronos
elected to implement the provisions of SFAS No. 123R in the fiscal year ended
June 30, 2005.

Recent Accounting Pronouncements:.

In May 2005, the Financial  Accounting Standards Board ("FASB") issued Statement
of  Financial  Accounting  Standards  No.  154,  "Accounting  Changes  and Error
Corrections-a replacement of APB Opinion No. 20 and FASB Statement No. 3" ("SFAS
154"). This Statement replaces APB Opinion No. 20, Accounting Changes,  and FASB
Statement No. 3, Reporting  Accounting Changes in Interim Financial  Statements,
and changes the requirements for the accounting for and reporting of a change in
accounting  principle.  This  Statement  applies  to all  voluntary  changes  in
accounting  principle.  It also  applies to changes  required  by an  accounting
pronouncement  in the unusual instance that the  pronouncement  does not include
specific  transition   provisions.   When  a  pronouncement   includes  specific
transition provisions, those provisions should be followed.

Opinion 20 previously required that most voluntary changes in accounting
principle be recognized by including in net income of the period of the change
the cumulative effect of changing to the new accounting principle. This
Statement requires retrospective application to prior periods' financial
statements of changes in accounting principle, unless it is impracticable to
determine either the period-specific effects or the cumulative effect of the
change. When it is impracticable to determine the period-specific effects of an
accounting change on one or more individual prior periods presented, this
Statement requires that the new accounting principle be applied to the balances
of assets and liabilities as of the beginning of the earliest period for which
retrospective application is practicable and that a corresponding adjustment be
made to the opening balance of retained earnings (or other appropriate
components of equity or net assets in the statement of financial position) for
that period rather than being reported in an income statement. When it is
impracticable to determine the cumulative effect of applying a change in
accounting principle to all prior periods, this Statement requires that the new
accounting principle be applied as if it were adopted prospectively from the
earliest date practicable. This Statement shall be effective for accounting
changes and corrections of errors made in fiscal years beginning after December
15, 2005. The Company does not believe that the adoption of SFAS 154 will have a
significant effect on its financial statements.

<PAGE>

In February 2006, the FASB issued FASB Statement No. 155, which is an amendment
of FASB Statements No. 133 and 140. This Statement; a) permits fair value
remeasurement for any hybrid financial instrument that contains an embedded
derivative that otherwise would require bifurcation, b) clarifies which
interest-only strip and principal-only strip are not subject to the requirements
of Statement 133, c) establishes a requirement to evaluate interests in
securitized financial assets to identify interests that are freestanding
derivatives or that are hybrid financial instruments that contain an embedded
derivative requiring bifurcation, d) clarifies that concentrations of credit
risk in the form of subordination are not embedded derivatives, e) amends
Statement 140 to eliminate the prohibition on a qualifying special-purpose
entity from holding a derivative financial instrument that pertains to a
beneficial interest other than another derivative financial instrument. This
Statement is effective for financial statements for fiscal years beginning after
September 15, 2006. Earlier adoption of this Statement is permitted as of the
beginning of an entity's fiscal year, provided the entity has not yet issued any
financial statements for that fiscal year. Management believes this Statement
will have no impact on the financial statements of the Company once adopted.

In March 2006, the FASB issued FASB Statement No. 156, which amends FASB
Statement No. 140. This Statement establishes, among other things, the
accounting for all separately recognized servicing assets and servicing
liabilities. This Statement amends Statement 140 to require that all separately
recognized servicing assets and servicing liabilities be initially measured at
fair value, if practicable. This Statement permits, but does not require, the
subsequent measurement of separately recognized servicing assets and servicing
liabilities at fair value. An entity that uses derivative instruments to
mitigate the risks inherent in servicing assets and servicing liabilities is
required to account for those derivative instruments at fair value. Under this
Statement, an entity can elect subsequent fair value measurement to account for
its separately recognized servicing assets and servicing liabilities. By
electing that option, an entity may simplify its accounting because this
Statement permits income statement recognition of the potential offsetting
changes in fair value of those servicing assets and servicing liabilities and
derivative instruments in the same accounting period. This Statement is
effective for financial statements for fiscal years beginning after September
15, 2006. Earlier adoption of this Statement is permitted as of the beginning of
an entity's fiscal year, provided the entity has not yet issued any financial
statements for that fiscal year. Management believes this Statement will have no
impact on the financial statements of the Company once adopted.

NOTE 4 -- INCOME TAXES

The composition of deferred tax assets and the related tax effects at March 31,
2006 and June 30, 2005 are as follows:


                                               March 31, 2006
                                                (Unaudited)     June 30, 2005
                                                -------------   -------------
Benefit from carryforward of capital and
 net operating losses                           $  6,792,930    $  6,091,927
Other temporary differences                          156,740         156,740
Less:
  Valuation allowance                             (6,949,670)     (6,248,667)
                                                -------------   -------------
Net deferred tax asset                          $          -    $          -
                                                =============   =============
The other temporary differences shown above relate primarily to impairment
reserves for intangible assets, and accrued and deferred compensation. The
difference between the income tax benefit in the accompanying statements of
operations and the amount that would result if the U.S. Federal statutory rate
of 34% were applied to pre-tax loss is as follows:


<TABLE>
<CAPTION>

                                                           March 31, 2006
                                                            (Unaudited)               June 30,2005
                                                   ---------------------------  ----------------------------
                                                                      % of                         % of
                                                        Amount    Pre-Tax Loss      Amount      Pre-Tax Loss
                                                   -------------  ------------  --------------  ------------
<S>                                                <C>                  <C>     <C>                    <C>
Benefit for income tax at federal statutory rate   $    893,694         34.0 %  $   2,411,998          34.0%
Benefit for income tax at state statutory rate           52,570          2.0 %        141,882           2.0%
Non-deductible expenses                                (245,262)        (9.3)%     (1,303,036)       (18.4)%
Increase in valuation allowance                        (701,003)       (26.7)%     (1,250,844)       (17.6)%
                                                   -------------  ------------  --------------  ------------
                                                   $       -              0.0%  $        -              0.0%
                                                   =============  ============  ==============  ============
</TABLE>

<PAGE>

The non-deductible expenses shown above related primarily to the amortization of
intangible assets and to the accrual of stock options for compensation using
different valuation methods for financial and tax reporting purposes.

At March 31, 2006, for Federal income tax and alternative minimum tax reporting
purposes, the Company has approximately $16.9 million of unused Federal net
operating losses, $2.3 million of capital losses and $11.8 million of unused
State net operating losses available for carryforward to future years. The
benefit from carryforward of such losses will expire in various years between
2006 and 2026 and could be subject to limitations if significant ownership
changes occur in the Company.

NOTE 5 - SEGMENTS OF BUSINESS

The Company operates principally in one segment of business: The Company
licenses, manufactures and distributes air movement and purification devices
utilizing the Kronos technology. For the three and nine months ended March 31,
2006 and the fiscal year ended June 30, 2005 the Company operated only in the
U.S.

NOTE 6 - EARNINGS PER SHARE

Weighted average shares outstanding used in the earnings per share calculation
were 107,372,928 and 88,245,584 for the three and nine months ended March 31,
2006 and 71,578,502 and 67,612,904 for the three and nine months ended March 31,
2005, respectively.

As of March 31, 2006, there were outstanding options to purchase 17,287,663
shares of the Company's common stock and outstanding warrants to purchase
42,300,000 shares of the Company's common stock. These options and warrants have
been excluded from the earnings per share calculation as their effect is
anti-dilutive. As of March 31, 2005, there were outstanding options and warrants
to purchase 12,813,812 shares of the Company's common stock and outstanding
warrants to purchase 42,300,000 shares of the Company's common stock. These
options have been excluded from the earnings per share calculation as their
effect is anti-dilutive.

NOTE 7 - NOTES PAYABLE

The Company had the following obligations as of March 31, 2006 and June 30,
2004,


                                         March 31, 2006
                                           (Unaudited)         June 30, 2005
                                        ---------------       ---------------
 Obligations to Cornell Capital(1)      $    2,240,000        $    4,000,000
 Obligation to HoMedics (2)                  2,575,000             2,400,000
 Obligation to current employees (3)           242,353               397,004
 Obligation for finance leases (4)                 -                  28,131
                                         --------------        ---------------
                                             5,057,353             6,825,135
Less:
 Current portion                             2,482,353             4,425,135
                                        ---------------       ---------------
 Total long term obligations net of
     current portion                    $    2,575,000        $    2,400,000
                                        ===============       ===============
(1) These notes have a one year term and bear interest at 12% with weekly
payments.

(2) This note has a 5 year term and bears interest at 6% with no payments
required until the earlier of Kronos receipt of royalty payments from HoMedics
sale of Kronos-based air purification products or February 1, 2007. This note
along with an obligation by HoMedics to provide Kronos with an additional
$750,000 in debt financing was issued along with warrants for the purchase of 40
million shares of the Company's common stock.

(3) These notes bear interest at the rate of 12%. They represent obligation to
current employees of the Company, which are due and payable in full.

(4) See Note 8 below.

<PAGE>

NOTE 8 - CAPITAL LEASES

The Company entered into a capital lease for the purpose of purchasing equipment
used in the research and product development center. Certain Officers of the
Company personally guaranteed the capital lease if the Company does not fulfill
its terms of the lease obligations. The leases were for 36 months and contained
bargain purchase provisions so that the Company could purchase the equipment at
the end of each lease. As of March 31, 2006, the Company satisfied its
obligations under the terms of the lease agreements.

Of the equipment that was purchased using capital leases, $10,650 was
capitalized and the remaining $65,782 was expensed through research and
development and cost of sales. In the three and nine months ended March 31,
2006, the Company paid $9,970 and $28,131 in principal and $382 and $3,120 in
interest on capital leases, respectively. In the three and nine months ended
March 31, 2005, the Company paid $6,047 and $22,016 in principal and $1,745 and
$6,744 in interest on capital leases, respectively.

NOTE 9 - CONSULTING AGREEMENTS

On October 31, 2003, the Company entered into a 10-month consulting agreement
with Joshua B. Scheinfeld and Steven G. Martin, principals of Fusion Capital,
for consulting services with respect to operations, executive employment issues,
employee staffing, strategy, capital structure and other matters as specified
from time to time. As consideration for their services, the Company issued
360,000 shares of its common stock. In accordance with EITF 96-18, the
measurement date was established as the contract date of October 31, 2003 as the
share grant was non-forfeitable and fully vested on that date. The stock was
valued on that date at $0.22 a share (the closing price for the Company's common
stock on the measurement date). The stock issuance has been recorded as a
prepaid consulting fee and was amortized to Professional Fee Expense ratably
over the ten month term of the contract. Under this contract, expenses of
$12,586 were recorded for the three and nine months ended March 31, 2005.

NOTE 10 - COMMITMENTS AND CONTINGENCIES

In October 2004, Kronos entered into agreements for up to $20.5 million in
equity and equity backed debt financing from Cornell Capital Partners. In
October 2004, Kronos sold 5 million unregistered shares of Kronos common stock
for gross proceeds of $500,000 to Cornell Capital Partners. Cornell Capital
Partners committed to provide $4 million pursuant to two Promissory Notes, which
was funded as follows: $2 million upon the filing of an SB-2 Registration
Statement and $2 million upon the SEC declaring the Registration Statement
effective. Kronos executed a Standby Equity Distribution Agreement for $20
million of funding which Kronos has the option to drawdown against in increments
as large as $1.5 million over the next fifteen months. In July 2005, Cornell
Capital Partners suspended until further notice weekly repayments of the Kronos
Promissory Note dated June 21, 2005. As of March 31, 2006, Kronos has received
$5.7 million in funding under these agreements and has repaid $1,760,000 of
principal on the Promissory Notes.

In October 2004, HoMedics agreed to extend repayment of Kronos debt and to
provide an additional $1 million in funding. HoMedics has agreed to provide
Kronos with an additional $1 million in financing - $925,000 in secured debt
financing and $75,000 for the purchase of additional warrants. In December 2005,
$175,000 was funded upon completion of Kronos testing of products under a
testing protocol co-developed by Kronos and HoMedics. An additional $750,000
will be paid to Kronos upon Kronos achieving two milestones (i) $250,000 shall
be funded upon obtaining tooling of the current prototype configuration and
device testing and performing to HoMedics' specifications, and (ii) $500,000
shall be funded upon the initial sale of Kronos-based air purifiers by HoMedics.
In addition, quarterly debt payments and the maturity date for existing debt
have been extended. Quarterly payments due on the outstanding $2,400,000 in
secured debt financing, which had been scheduled to begin in August 2004, will
be due the earlier of Kronos receipt of royalty payments from HoMedics sale of
Kronos-based air purification products or two years. The maturity date of the
$2,400,000 in debt has been extended from May 2008 to October of 2009; the
maturity date on the $925,000 will also be October 2009. The interest rate will
remain at 6% for the $2,400,000 in debt; the rate will also be 6% on the
additional debt. HoMedics increased their potential equity position in Kronos to
30% of Kronos common stock on a fully diluted basis. In connection with the
October 2004 agreements, Kronos issued HoMedics a warrant to buy 26.5 million
shares of Kronos common stock. As a result of this debt restructuring, the
Company recognized a loss of $3,857,467 during the fiscal year ended June 30,
2005. This loss represented the reacquisition price less the net carrying value
of the debt restructuring. The reacquisition price is made up of $2,400,000
which is the amount of the new debt and $3,361,161 which represents the value of
the warrants using the Black-Scholes method. The net carrying value is the
$2,400,000 which is the old debt less the unamortized debt discount of $496,296.

<PAGE>

Daniel R. Dwight, President and Chief Executive Officer, and the Company entered
into an Employment agreement effective as of November 15, 2001. The initial term
of Mr. Dwight's Employment Agreement was for 2 years and will automatically
renew for successive 1 year terms unless Kronos or Mr. Dwight provide the other
party with written notice within 3 months of the end of the initial term or any
subsequent renewal term. The Board of Directors renewed Mr. Dwight's Employment
Agreement on August 13, 2003 and again on August 15, 2004 and August 15, 2005.
Mr. Dwight's Employment Agreement provides for base cash compensation of
$180,000 per year. In April 2006, Mr. Dwight's contract was amended for a base
compensation increase to $225,000. Mr. Dwight is eligible for annual incentive
bonus compensation in an amount equal to Mr. Dwight's annual salary based on the
achievement of certain bonus objectives. In addition, Kronos granted Mr. Dwight
1,000,000 immediately vested and exercisable, ten-year stock options at various
exercise prices. Mr. Dwight will be entitled to fully participate in any and all
401(k), stock option, stock bonus, savings, profit-sharing, insurance, and other
similar plans and benefits of employment.

Richard F. Tusing, Chief Operating Officer, and the Company entered into an
Employment agreement effective as of January 1, 2003. The initial term of Mr.
Tusing's Employment Agreement is for 2 years and will automatically renew for
successive 1 year terms unless Kronos or Mr. Tusing provide the other party with
written notice within 3 months of the end of the initial term or any subsequent
renewal term. The Board of Directors renewed Mr. Tusing's Employment Agreement
on October 1, 2004 and again on October 1, 2005. Mr. Tusing's Employment
Agreement provides for base cash compensation of $160,000 per year. Mr. Tusing
will be entitled to fully participate in any and all 401(k), stock option, stock
bonus, savings, profit-sharing, insurance, and other similar plans and benefits
of employment.

NOTE 11 - SUBSEQUENT EVENTS

In April 2006, Kronos issued 4,488,330 shares of common stock for $250,000 to
Cornell under the terms of our Standby Equity Distribution Agreement. The
proceeds were used to make payments on the Promissory Note dated March 7, 2005
and to increase the Company's cash reserves.

In April 2006, the Company paid off in full all its outstanding capital leases
that had been entered into for the purpose of purchasing equipment used in the
research and product development center.

In April 2006, Kronos was invited to serve as a member and an industrial partner
in the Federal Aviation Administration's (FAA) Air Transportation Airliner Cabin
Environment Research Center of Excellence (ACER CoE). In this capacity, Kronos
will provide its real-time decontamination, air filtration, purification and
technology expertise to evaluate and develop solutions that proactively address
and improve cabin air quality. The program, led by the FAA, includes senior
executives from aerospace equipment manufacturers and leading American
universities.

<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

INTRODUCTORY STATEMENTS

FORWARD LOOKING STATEMENTS AND ASSOCIATED RISKS

FORWARD-LOOKING STATEMENTS AND ASSOCIATED RISKS. THIS FILING CONTAINS
FORWARD-LOOKING STATEMENTS, INCLUDING STATEMENTS REGARDING, AMONG OTHER
THINGS:(A) OUR PROJECTED SALES AND PROFITABILITY, (B) OUR GROWTH STRATEGIES, (C)
ANTICIPATED TRENDS IN OUR INDUSTRY, (D) OUR FUTURE FINANCING PLANS, (E) OUR
ANTICIPATED NEEDS FOR WORKING CAPITAL, AND (F) THE BENEFITS RELATED TO OUR
OWNERSHIP OF KRONOS AIR TECHNOLOGIES, INC. IN ADDITION, WHEN USED IN THIS
FILING, THE WORDS "BELIEVES," "ANTICIPATES," "INTENDS," "IN ANTICIPATION OF,"
"EXPECTS," AND SIMILAR WORDS ARE INTENDED TO IDENTIFY CERTAIN FORWARD-LOOKING
STATEMENTS. THESE FORWARD-LOOKING STATEMENTS ARE BASED LARGELY ON OUR
EXPECTATIONS AND ARE SUBJECT TO A NUMBER OF RISKS AND UNCERTAINTIES, MANY OF
WHICH ARE BEYOND OUR CONTROL. ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THESE
FORWARD-LOOKING STATEMENTS AS A RESULT OF VARIOUS FACTORS, INCLUDING, WITHOUT
LIMITATION, THE RISKS OUTLINED UNDER "FACTORS AFFECTING KRONOS' BUSINESS AND
PROSPECTS" AND MATTERS DESCRIBED IN THIS FILING GENERALLY. IN LIGHT OF THESE
RISKS AND UNCERTAINTIES, THERE CAN BE NO ASSURANCE THAT THE FORWARD-LOOKING
STATEMENTS CONTAINED IN THIS FILING WILL IN FACT OCCUR. WE DO NOT UNDERTAKE ANY
OBLIGATION TO PUBLICLY RELEASE THE RESULTS OF ANY REVISIONS TO THESE
FORWARD-LOOKING STATEMENTS THAT MAY BE MADE TO REFLECT ANY FUTURE EVENTS OR
CIRCUMSTANCES.

GENERAL

Kronos Advanced Technologies, Inc. is an application development and licensing
company that has developed and patented technology that fundamentally changes
the way air is moved, filtered and sterilized. Kronos is pursuing
commercialization of its proprietary technology for a limited number of
applications in a limited number of markets; and if we are successful, we intend
to pursue additional applications and to enter additional markets in the future.
To date, our ability to execute our strategy has been restricted by our limited
amount of capital.

Technology Description and Benefits

The proprietary Kronos technology involves the management of corona discharge by
applying of high voltage management across paired electrical grids to create an
ion exchange. Applications for efficient high voltage management, efficient
corona discharge and ion exchange include but are not limited to:

     o    air movement, including dielectric fluid movement and propulsion;
     o    air   purification,    including   particulate   removal,    biohazard
          destruction, chemical and industrial gas treatment, and odor removal;
     o    temperature and environmental management,  including space heating and
          cooling;
     o    microchip, MEMS and other electronics devices and components cooling;
     o    air  management,  including  sorting and  separation of air streams by
          particle content;
     o    sound generation,  including high fidelity sound recreation and active
          noise cancellation;
     o    high voltage management,  including  development of high voltage power
          supplies and control of energy surges and electrical discharges;
     o    control  of water  and  moisture  content  in air  streams,  including
          dehumidification and humidification; and
     o    water treatment,  including water  purification,  ionization and water
          desalination.

Kronos is focused on prioritizing the Company's resources on developing and
licensing Kronos' proprietary technology for air movement and purification
applications to address the indoor air quality market. The Kronos technology has
numerous valuable characteristics for applications in the indoor air quality
market, including moving air and gases at high velocities while removing odors,
smoke and particulates and killing pathogens, including bacteria, mold and
spores. The technology is cost-effective and is more energy efficient than
current alternative fan and filter (including HEPA filter and ultraviolet light
based) technologies.

<PAGE>

Although no commercial products using the Kronos technology have been sold to
date, in March 2005, the Company and its strategic consumer products partner,
HoMedics, expanded production beyond the initial prototypes and increased
product testing to complete the product claims platform. In August 2005, Kronos
received initial shipment of products from its low cost, contract manufacturers
in Mexico and China. In October 2005, Kronos completed internal testing of these
products under a testing protocol co-developed by Kronos and HoMedics. In
December 2005, Kronos shipped a prototype device designed and built under
specific customer specifications to a leading auto manufacturer for their
testing and evaluation and prepared for shipment (awaiting customer
documentation) a prototype device designed and built under specific customer
specifications to a leading business jet manufacturer. Further in December 2005,
the Company executed a non-exclusive license agreement with EOL, LLC, a Russian
Federation company, for manufacturing and distributing Kronos-based commercial
standalone products in Russia and other select Commonwealth of Independent
States, and shipped products to additional commercial customers for testing and
evaluation of the purification capability of the Kronos technology in
residential, commercial and industrial environments.

A number of the scientific claims of the Kronos technology have been tested by
the U. S. and foreign governments, multi-national companies and independent
testing facilities. To date, independent laboratory testing has verified the
filtration and sterilization capability of the Kronos technology.

     Filtration Testing Results:

     o    Aerosol and Air Quality  Research  Laboratory - up to 99.8% filtration
          of 0.02 to 0.20 micron (20 to 200 nanometers) size particles;
     o    LMS   Industries  -  removal  of  over  99.97%  of  0.10  micron  (100
          nanometers) and above size particles using HVAC industry's ASHRAE 52.2
          testing standard for filtration;
     o    MicroTest   Laboratories   -  HEPA  Clean  Room  Class  1000   quality
          particulate reduction;
     o    Intertek  -  tobacco  smoke   elimination  tests  in  accordance  with
          ANSI/AHAM  AC-1-1988  standard  entitled  "American  National Standard
          Method  for  Measuring  Performance  of  Portable  Household  Electric
          Cord-Connected  Room Air  Cleaners,"  which  demonstrated  a Clean Air
          Delivery  Rate (CADR) for the Kronos air  purifier of over 300 for the
          larger size  Kronos air  purifier  and 80 for the  smaller  size using
          consumer  filtration  testing  standards for the  Association  of Home
          Appliance Manufacturers (AHAM).

Sterilization Testing Results:

     o    Disinfection Research Institute  Sterilization  Laboratory in Moscow -
          100%  decontamination  of room infected with bacteria  (Staphylococcus
          aureus  strain  906 (S.  aureus)  and  Bacillus  cereus  strain 96 (B.
          cereus);
     o    Institute  for  Veterinary  Medicine  in the  Ukraine  -  destroy  and
          sterilize  air which had been  inseminated  with  Anthrax  and  E.coli
          spores;
     o    New Hampshire Materials  Laboratory - up to 95% reduction of hazardous
          gases, including numerous carcinogens found in cigarette smoke;
     o    Battelle PNNL - 95% destruction of Bg (anthrax simulant);
     o    Dr. Sergey Stoylar, a bacteriologist from the American Bacteriological
          Society  -  100%  destruction  of  Bacillus   subtilis  168  (bacteria
          simulant).

Market Segmentation

Kronos' initial business development strategy is to sell and license the Kronos
technology to six distinct air quality market segments: (1) air movement and
purification (residential, health care, hospitality, and commercial facilities);
(2) air purification for unique spaces (clean rooms, airplanes, automotive, and
cruise ships); (3) specialized military (naval vessels, closed vehicles and
mobile facilities); (4) embedded cooling and cleaning (electronic devices and
medical equipment); (5) industrial scrubbing (produce storage and diesel and
other emissions); and (6) hazardous gas destruction (incineration and chemical
facilities).

Kronos' focus is on the first four of these market segments which are described
in more detail below. Kronos is currently developing products for the air
movement and purification, air purification for unique spaces, and specialized
military markets through specific customer contracts. Kronos is currently
undertaking research and development in the embedded micro cooling market using
Company funds and a third party grant. These contracts and grant are described
in more detail in the Technology Application and Product Development section of
this filing.

     o    Air Movement and Purification.  Indoor air pollution,  including "sick
          building syndrome" and "building related illness," is primarily caused
          by  inadequate  ventilation,  chemical  contaminants  from  indoor and
          outdoor  sources and biological  contaminants.  There is also a demand
          for  smaller  devices  that move,  heat and  deodorize  the indoor air
          stream. The addressable air movement and purification  segment is made
          up of four principal target markets: (1) residential, (2) health care,
          (3) hospitality and (4) commercial.

<PAGE>

     o    Air  Purification  for  Unique  Spaces.  Electronics,   semiconductor,
          pharmaceutical,  aerospace, medical and many other producers depend on
          clean room technology.  As products such as electronic  devices become
          smaller, the chance of contamination in manufacturing  becomes higher.
          For  pharmaceutical   companies,   clean,  safe  and  contaminant-free
          products are  imperative to  manufacturing  and  distributing a viable
          product.  Other  potential  applications  for  the  Kronos  technology
          include closed  environments  such as  automobiles,  aircraft,  cruise
          ships and other  transportation  modes that require  people to breathe
          contaminated, re-circulated air for extended periods.

     o    Specialized  Military.  Military  personnel  face  the  worst  of  all
          possible worlds:  indoor air pollution,  often in very confined spaces
          for extended periods,  combined with the threat of biological warfare,
          nuclear  fallout,  and other  foreign  elements.  We believe  that the
          military market segment offers Kronos a unique opportunity to leverage
          the  technical  and funding  resources of the U. S. military to expand
          Kronos'  ability to develop  and produce  Kronos-based  air movers and
          purifiers for applications  that require these products to be embedded
          into ventilation systems to address the needs of military personnel.

     o    Embedded  Cooling.  Heat generation is becoming a major  bottleneck in
          high density electronics.  We believe that the embedded cooling market
          segment   offers  Kronos  a  near  term   opportunity  to  develop  an
          alternative  to fans for air movement  and cooling  inside of personal
          computers , servers and medical  diagnostic  equipment and a long term
          opportunity  to develop  micro  channel  cooling  solutions for future
          generation microchips.

Technology Application and Product Development

To best serve Kronos' targeted market segments, our Company is developing
specific product applications across two distinct product application platforms.
A Kronos device can be either used as a standalone product or can be embedded.
Standalone products are self-contained and only require the user to plug the
Kronos device into a wall outlet to obtain air movement and filtration for their
home, office or hotel room. Embedded applications of the Kronos technology
require the technology be added into another system such as a building
ventilation system for more efficient air movement and filtration or into an
electrical device such as computer or medical equipment to replace the cooling
fan.

                               Standalone Platform

Residential Products. In October 2002, Kronos and HoMedics executed a Licensing
Agreement granting HoMedics certain rights with respect to the distribution of
the Kronos proprietary technology to the consumer. The agreement provides for
exclusive North American, Australian and New Zealand retail distribution rights
for next generation consumer air movement and purification products based on the
patented Kronos technology. The initial term of the agreement is three and one
half years from the initial sale of consumer air purification products by
HoMedics, which shall be no later than December 31, 2006, with the option to
extend the Licensing Agreement for six additional years. Kronos was compensated
through an initial royalty payment and will receive ongoing quarterly royalty
payments based on a percentage of sales. HoMedics will pay minimum royalty
payments of at least $2 million during the initial three and a half year term
and on-going royalty payments to extend the agreement. Kronos will retain the
rights to all of its intellectual property. HoMedics commitment includes funding
a marketing and advertising campaign to promote the Kronos-based product line.
The products will be distributed by HoMedics. HoMedics currently distributes
their products through major domestic retailers, including Wal-Mart, Home Depot,
Sears, Bed Bath & Beyond, and Linens 'N Things.

We believe the Company has successfully completed the development of a
Kronos-based consumer standalone air purifier that is an efficient, high quality
product which is cost effective and easy to operate. In March 2005, Kronos and
HoMedics began expanding production development beyond the initial prototypes
and initiated increased product testing to complete the product claims platform.
In March and April 2005, Kronos modified the HoMedics design and ordered
prototype production devices from Kronos' preferred vendor along with select
components from HoMedics preferred vendors. In August 2005, Kronos received
initial shipment of products from its low cost, contract manufacturer in Mexico
and China. In October 2005, Kronos completed internal testing of these products
under a testing protocol co-developed by Kronos and HoMedics. In December 2005,
HoMedics funded the Company a further $175,000 upon acceptance of Kronos testing
results. In February 2006, HoMedics agreed to fund any further efforts required
by Kronos in support of HoMedics effort to bring the consumer standalone air
purifier to market.

Commercial and Other Standalone Products. Utilizing our recently expanded
product development resources, Kronos completed the initial design, development
and production of a series of small multifunctional devices that can be used as
kitchen range hoods, space heaters, vaporizers, disinfectors, deodorizers and/or
fans. Based on the proprietary Kronos technology, these devices are currently
undergoing testing and evaluation. Kronos has been meeting with potential
strategic partners for manufacturing, marketing, selling and distributing these
Kronos-based products.

<PAGE>

In December 2005, Kronos executed a non-exclusive License Agreement with EOL,
LLC, a Russian Federation corporation. Based in Korolev, Moscow Region, Russia,
EOL will leverage the Kronos technology to produce, market, and distribute
Kronos commercial air purification products, bacteriological and virus
destruction devices and space heaters in select Commonwealth of Independent
States. The agreement comes after successful completion of multiple tests in
Eastern Europe, which found the Kronos technology capable of decontaminating
rooms infected with airborne viruses and bacteria. Under the terms of the
five-year agreement, EOL will provide Kronos a fixed percentage royalty on every
product sold, as well as upfront licensing and quarterly maintenance fees. Based
on contractual milestones, EOL is required to: (i) complete initial product
design by March 2006; (ii) complete initial product prototypes by June 2006; and
(iii) make product available for customer purchase by September 2006. EOL plans
to assemble the finished products in Russia from components supplied both
locally and from contract manufacturers in China. The products will be marketed
and distributed in Russia, Ukraine, Kazakhstan, Moldova and Byelorussia. In
March 2006, EOL achieved the first milestone: initial design of a wall mounted
air sterilizer for the health care market.

                                Embedded Platform

Residential Products. In May 2005, Kronos initiated a strategic relationship
with IKEA of Sweden. In September 2005, Kronos shipped its initial prototype
device to IKEA for testing and evaluation. In March 2006, the customer decided
not to proceed further at this time with implementation of a new technology
solution. Following on this effort by Kronos during the quarter ended March 31,
2006, several leading global home appliance manufacturers initiated discussions
with Kronos with an interest in using the Kronos technology for developing
select residential applications, including silent kitchen range hoods. With
specific customer input, Kronos is designing and developing prototypes for
additional customer demonstration and evaluation.

Military Products. The U. S. Department of Defense and Department of Energy have
provided Kronos with various grants and contracts to develop, test and evaluate
the Kronos technology for embedded applications.

U.S. Navy SBIR Contracts. In November 2002, the U. S. Navy awarded Kronos a
Small Business Innovation Research Phase II contract worth $580,000. The Phase
II contract (commercialization phase) is an extension of the Phase I and the
Phase I Option work that began in 2001. It is intended that the Kronos devices
developed under this contract will be embedded in existing HVAC systems in order
to move air more efficiently than traditional, fan-based technology. During
Phase II, Kronos developed and produced a fully controlled device that
represents a "cell" of an advanced distributive air management system with
medium capacity airflow in a U. S. Navy unique environment. The "cell" has been
designed to be easily adjustable to a variety of parameters such as duct size,
airflow requirements, and air quality. The goal of this development work is to
significantly reduce or replace altogether the current HVAC air handling systems
on naval ships. In May 2005, Kronos shipped the device to Northrop Grumman for
testing and evaluation. Based on the success of these initial tests, Northrop
Grumman requested additional modifications and improvements to the device.
Northrop Grumman is scheduling further testing. As of March 31, 2006, the U. S.
Navy had provided Kronos with $580,000 in funding for this effort.

As part of its air management system, Kronos has developed and intends to test
the air filtration mechanism capable of performing to HEPA quality standards. We
believe that Kronos devices could replace current HEPA filters with a permanent,
easily cleaned, low-cost solution. Among the technical advantages of the Kronos
technology over HEPA filters is the ability of the Kronos-based devices to
eliminate the energy burden on air handling systems, which must generate high
levels of backpressure necessary to move air through HEPA-based systems.
Kronos-based devices enhance the air flow while providing better than HEPA level
filtration.

Kronos is seeking to leverage its military application development work with the
U. S. Navy to develop and produce air handlers and purifiers for commercial and
industrial facilities. A future potential commercial line of Kronos-based air
handlers and purifiers would attempt to address the specific air quality issues,
including bacteria and other germs, found in large enclosed spaces such as
office buildings and multi-dwelling residential complexes, while providing more
efficient air movement.

Transportation Products. In January 2003, Kronos executed a Development and
Acquisition Agreement with a premier business jet manufacturer. The Agreement
was the direct result of initial prototype development work performed by the
Kronos Research Team with input from the customer in 2002. The Kronos devices
being designed and manufactured under this contract will need to meet all FAA
safety standards, including environmental, flammability and electromagnetic
interference (EMI). The Company has completed product design and development
based on the customer's specific product application requirements. We have
completed testing and prepared for shipment the prototype product. We are
waiting for shipment instructions from the customer.

<PAGE>

In August 2005, Kronos extended its work into the transportation industry by
signing a Prototype Development and Evaluation Agreement with a leading luxury
automotive manufacturer. According to various industry reports, the amount of
time Americans have spent in their cars has risen 236 percent since 1982 (with
one report from Time Magazine noting an average motorist will spend more than 5
years stuck in traffic alone), providing optimum air circulation in automobiles
is not only a comfort factor, but can also be a critical means of improving air
quality and helping to prevent viruses and allergens that may otherwise
accumulate in filtration systems. The Kronos product has been designed and
manufactured to meet exacting customer standards for placement inside of
automobile passenger cabins. The customer is evaluating various potential
applications for the technology.

In April 2006, Kronos was invited to serve as a member and an industrial partner
in the Federal Aviation Administration's (FAA) Air Transportation Airliner Cabin
Environment Research Center of Excellence (ACER CoE). In this capacity, Kronos
will provide its real-time decontamination, air filtration, purification and
technology expertise to evaluate and develop solutions that proactively address
and improve cabin air quality. The program, led by the FAA, includes senior
executives from aerospace equipment manufacturers and leading American
universities.

Microelectronics Cooling Products. In December 2004, Kronos and the University
of Washington were awarded funding for a research and technology development
project entitled "Heat Transfer Technology for Microelectronics and MEMS" by the
Washington Technology Center ("WTC"). The objective of the project is to develop
a novel energy-efficient heat transfer technology for cooling microelectronics.
Thermal management for microelectronics and MEMS systems is a challenge.
Existing cooling devices aren't meeting increasing needs for energy consumption
and heat dissipation. Kronos air handling technology is an emerging technology
that uses an electric field to exert force on ionized gas. Kronos is attempting
to develop an improved microchip air handling system that is smaller in size,
has high speed airflow, allows more targeted delivery of cooling to areas of
highest heat and is compatible with current processes. WTC will contribute
$40,000 to the project, with Kronos contributing $8,000, plus $32,000 in in-kind
services, including use of the Kronos Research and Product Development Facility.
During the quarter ended March 31, 2006, Kronos and the University of Washington
continued research into development of an energy-efficient heat transfer
technology for cooling microelectronics and initiated fabrication of a prototype
product based on the proprietary Kronos technology. In January 2006, Kronos and
the University of Washington conducted a successful bench scale demonstration of
micron cooling of a MEMS chip.

Patents and Intellectual Property

Kronos has received notification that nine of its patents have been allowed for
issuance by the United States Patent and Trademark Office. These patents are
considered utility patents which describe fundamental innovations in the
generation, management and control of electrostatic fluids, including air
movement, filtration and purification. Each of the patents contain multiple part
claims for both general principles as well as specific designs for incorporating
the Kronos technology into air movement, filtration and purification products.
The patents provide protection for both specific product implementations of the
Kronos technology, as well as more general processes for applying the unique
attributes and performance characteristics of the technology.


                                  U.S. Patents

<TABLE>
<CAPTION>

    Date       U.S. Patent #     Patent Title          Description                          Protection
    ----       -------------     ------------          -----------                          ----------
<S>                                                                                         <C>
January        Notice of         Electrostatic Fluid   effective powering of the            2022
2006           Allowance         Accelerator - Power   electrodes
                                 Management

November       6,963,479         Electrostatic Fluid   advanced voltage management          2023
2005                             Accelerator -         impacts air  filtration and
                                 Advanced  Geometries  sterilization, air flow and
                                                       ozone

<PAGE>

August         6,937,455         Spark Management      analysis, detection and              2022
2005                             Method and Device     prevention of sparks in a
                                                       high voltage field -
                                                       creating safe, effective
                                                       electrostatic technology
                                                       products

July           6,919,698         Voltage Management    materials and geometry               2023
2005                             for Electrostatic     allowing for spark free
                                 Fluid Accelerator     operation and use of light
                                                       weight, inexpensive
                                                       materials as the electrodes

May            Notice of         Electrostatic Fluid   placement, utilization and           2022
2005           Allowance         Accelerator Design    geometries of the
                                 Geometries            electrodes - impacts air
                                                       flow, filtration and
                                                       sterilization

May            6,888,314         Electrostatic Fluid   electrode design geometries          2022
2005                             Accelerator -         and attributes including
                                 Electrode Design      micro channeling to achieve
                                 Geometries            unique air movement and
                                                       purification performance

April          6,727,657         Electrostatic Fluid   synchronization of multiple          2022
2004                             Accelerator for and   stages of arrays -
                                 a Method of           increasing air flow and air
                                 Controlling Fluid     flow efficiency

December       6,664,741         Method of and         ratio of voltage for                 2022
2003                             Apparatus for         producing ion discharge to
                                 Electrostatic Fluid   create air movement and
                                 Acceleration Control  base level filtration
                                 of a Fluid Flow

January        6,504,308         Electrostatic Fluid   electrode density core for           2019
2003                             Accelerator           producing ion discharge to
                                                       create air movement and
                                                       base level filtration
</TABLE>

                              International Patents

In November 2004, Kronos received formal notification from the Commonwealth of
Australia Patent Office indicating that its application entitled "Electrostatic
Fluid Accelerator" has been examined and allowed for issuance as an Australian
patent. In December 2005, Kronos received formal notification from the Mexican
Institute of Industrial Property indicating that its application entitled
"Electrostatic Fluid Accelerator" has been examined and allowed for issuance as
a Mexican patent. There are a number of other patent applications corresponding
to Kronos' nine U.S. Patents that have been filed and are pending outside of the
United States.

Kronos intends to continue to aggressively file patent applications in the U.S.
and internationally. A number of additional patent applications have been filed
for, among other things, the control and management of electrostatic fluid
acceleration. These additional patent applications are either being examined or
are awaiting examination by the Patent Office.

<PAGE>

CRITICAL ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with
accounting principles generally accepted in the United States requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosures of contingent assets and liabilities at
the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.

Allowance for Doubtful Accounts. If necessary, we provide a reserve against our
receivables for estimated losses that may result from our customers' inability
to pay. These reserves are based on potential uncollectible accounts, aged
receivables, historical losses and our customers' credit-worthiness. Should a
customer's account become past due, we generally will place a hold on the
account and discontinue further shipments and/or services provided to that
customer, minimizing further risk of loss.

Valuation of Goodwill, Intangible and Other Long Lived Assets. We use
assumptions in establishing the carrying value, fair value and estimated lives
of our long-lived assets and goodwill. The criteria used for these evaluations
include management's estimate of the asset's ability to generate positive income
from operations and positive cash flow in future periods compared to the
carrying value of the asset, the strategic significance of any identifiable
intangible asset in our business objectives, as well as the market
capitalization of Kronos. We have used certain key assumptions in building the
cash flow projections required for evaluating the recoverability of our
intangible assets. We have assumed revenues from the following applications of
the Kronos technology: consumer stand-alone devices, assisted care/skilled
nursing stand-alone devices, embedded devices in the hospitality industry and in
specialized military applications. Expenses/cash out flows in our projections
include sales and marketing, production, distribution, general and
administrative expenses, research and development expenses and capital
expenditures. These expenses are based on management estimates and have been
compared with industry norms (relative to sales) to determine their
reasonableness. We use the same key assumptions for our cash flow evaluation as
we do for internal budgeting, lenders and other third parties; therefore, they
are internally and externally consistent with financial statement and other
public and private disclosures. We are not aware of any negative implications
resulting from the projections used for purposes of evaluating the
appropriateness of the carrying value of these assets. If assets are considered
to be impaired, the impairment recognized is the amount by which the carrying
value of the assets exceeds the fair value of the assets. Useful lives and
related amortization or depreciation expense are based on our estimate of the
period that the assets will generate revenues or otherwise be used by Kronos.
Factors that would influence the likelihood of a material change in our reported
results include significant changes in the asset's ability to generate positive
cash flow, loss of legal ownership or title to the asset, a significant decline
in the economic and competitive environment on which the asset depends,
significant changes in our strategic business objectives, and utilization of the
asset.

Valuation of Deferred Income Taxes. Valuation allowances are established, when
necessary, to reduce deferred tax assets to the amount expected to be realized.
The likelihood of a material change in our expected realization of these assets
is dependent on our ability to generate future taxable income, our ability to
deduct tax loss carryforwards against future taxable income, the effectiveness
of our tax planning and strategies among the various tax jurisdictions that we
operate in, and any significant changes in the tax treatment received on our
business combinations.

Revenue Recognition. We recognize revenue in accordance with Securities and
Exchange Commission Staff Bulletin 104 ("SAB 104"). Further, Kronos Air
Technologies recognizes revenue on the sale of custom-designed contract sales
under the percentage-of-completion method of accounting in the ratio that costs
incurred to date bear to estimated total costs. For uncompleted contracts where
costs and estimated profits exceed billings, the net amount is included as an
asset in the consolidated balance sheet. For uncompleted contracts where
billings exceed costs and estimated profits, the net amount is included as a
liability in the consolidated balance sheet. Sales are reported net of
applicable cash discounts and allowances for returns.

RESULTS OF OPERATIONS

Consolidated Statement of Operations For the Quarter Ended March 31, 2006.

Our net loss for the nine months ended March 31, 2006 was $2,628,516 compared
with a net loss of $5,944,850 for the corresponding period of the prior year.
The decrease in the net loss for the nine months ended March 31, 2006, as
compared to the prior year, was principally the result of a $3,857,467 loss on
debt incurred during the nine months ended March 31, 2005 and a $501,081 or 29%
increase in selling, general and administrative expenses.

Revenue. Revenues are generated through sales of services for design and
development of Kronos devices by Kronos Air Technologies, Inc. Revenues for the
nine months ended March 31, 2006 were $37,500 compared with $430,379 in the
prior year. Revenues for the nine months ended were from fees associated with
our prototype development and acquisition agreement with a luxury automotive
manufacturer and our new licensing partner in Russia. Revenues for the nine
months ended March 31, 2005 were primarily from our U. S. Navy SBIR Phase II and
U. S. Army SBIR Phase II contracts.

<PAGE>

Cost of Sales. Cost of sales for the nine months ended March 31, 2006 was $8,449
(or 23% of sales) compared with $375,397 (or 87%) for the prior year. Cost of
sales for the nine months ended March 31, 2006 were primarily labor associated
with our prototype development and acquisition agreement with a luxury
automotive manufacturer. Cost of sales for the nine months ended March 31, 2005
were primarily development costs associated with our U. S. Navy SBIR and U. S.
Army SBIR contracts.

Selling, General and Administrative Expenses. Selling, General and
Administrative expenses for the nine months ended March 31, 2006 increased
$501,081 from the corresponding period of the prior year to $2,233,537. The
increase was principally the result of a $176,245 increase in amortization and
depreciation as a result of the increase in the amortization of capitalized
patent costs and Cornell Capital funding costs; $154,445 increase in research
and development costs associated with developing new applications for the Kronos
technology; and a $141,693 increase in professional services as a result of the
Company's increase in costs for investor and press relations activities and
legal costs associated with licensing and development agreements with new
strategic partners.

Interest expense. Interest expense for the nine months ended March 31, 2006 was
$424,030 compared to $411,324 for the corresponding period of the prior year.

Consolidated Balance Sheet as of March 31, 2006

Our total assets at March 31, 2006 were $2,591,709 compared with $3,959,837 at
June 30, 2005. Total assets at March 31, 2006 and June 30, 2005 were comprised
primarily of $2,016,975 and $2,138,814, respectively, of patents/intellectual
property and $469,320 and $1,554,906, respectively, of cash. Total current
assets at March 31, 2006 and June 30, 2005 were $572,708 and $1,818,396,
respectively, while total current liabilities for those same periods were
$3,566,316 and $5,420,217, respectively, creating a working capital deficit of
$2,993,608 and $3,601,821 at each respective period end. This working capital
deficit is primarily due to short term borrowings from Cornell Capital Partners.

Stockholders' deficit as of March 31, 2006 was ($3,549,607). The sale and
issuance of common stock for cash ($2,860,000) and the issuance of options for
services ($79,290) was partially offset by a $2,628,516 net loss for the nine
months ended March 31, 2006.

LIQUIDITY AND CAPITAL RESOURCES

Historically, we have relied principally on the sale of common stock and secured
debt and customer contracts for research and product development to finance our
operations.

In October 2004, Kronos entered into agreements for up to $20,500,000 in equity
and equity backed debt financing from Cornell Capital Partners. In October 2004,
Kronos sold 5 million unregistered shares of Kronos common stock for gross
proceeds of $500,000 to Cornell Capital Partners. Cornell Capital Partners
committed to provide $4,000,000 pursuant to two Promissory Notes, which have
been funded as follows: $2,000,000 upon the filing an SB-2 Registration
Statement and $2,000,000 upon the SEC declaring the Registration Statement
effective. Kronos executed a Standby Equity Distribution Agreement for
$20,000,000 of funding which Kronos has the option to drawdown against in
increments as large as $1,500,000 over the next fifteen months. As of June 30,
2005, Kronos had received $4,500,000 in funding under these agreements. In July
2005, Cornell Capital Partners suspended until further notice weekly repayments
of the Kronos Promissory Note dated June 21, 2005 and suspended for one month
weekly repayments of the Kronos Promissory Note dated March 7, 2005. In
September 2005, Cornell Capital Partners suspended for one month weekly
repayments of the Kronos Promissory Note dated March 7, 2005. As of March 31,
2006, Kronos has received $5,725,000 in funding under these agreements and has
repaid $1,760,000 of principal on the Promissory Notes.

In October 2004, HoMedics agreed to extend repayment of Kronos debt and to
provide an additional $1 million in funding. HoMedics has agreed to provide
Kronos with an additional $1 million in financing - $925,000 in secured debt
financing and $75,000 for the purchase of additional warrants. In December 2005,
$175,000 was funded upon completion of Kronos testing of products under a
testing protocol co-developed by Kronos and HoMedics. An additional $750,000
will be paid to Kronos upon Kronos achieving two milestones (i) $250,000 shall
be funded upon obtaining tooling of the current prototype configuration and
device testing and performing to HoMedics' specifications, and (ii) $500,000
shall be funded upon the initial sale of Kronos-based air purifiers by HoMedics.
In addition, quarterly debt payments and the maturity date for existing debt
have been extended. Quarterly payments due on the outstanding $2,400,000 in
secured debt financing, which had been scheduled to begin in August 2004, will
be due the earlier of Kronos receipt of royalty payments from HoMedics sale of
Kronos-based air purification products or two years. The maturity date of the
$2,400,000 in debt has been extended from May 2008 to October of 2009; the
maturity date on the $925,000 will also be October 2009. The interest rate will
remain at 6% for the $2,400,000 in debt; the rate will also be 6% on the
additional debt. HoMedics increased their potential equity position in Kronos to
30% of Kronos common stock on a fully diluted basis.

<PAGE>

Net cash flow used in operating activities was $1,983,667 for the nine months
ended March 31, 2006. We were able to satisfy most of our cash requirements for
this period from the proceeds of the $4,000,000 Promissory Notes with Cornell
Capital Partners and from the incremental $175,000 in debt financing from our
strategic partner, HoMedics, Inc.

We estimate that achievement of our business plan will require substantial
additional funding. We anticipate that the source of funding will be obtained
pursuant to senior debt funding from the HoMedics Secured Promissory Note;
equity funding from the Cornell Capital Standby Equity Distribution Agreement;
and/or the sale of additional equity in our Company; cash flow generated from
government grants and contracts; and cash flow generated from customer revenue.
There are no assurances that these sources of funding will be adequate to meet
our cash flow needs.

GOING CONCERN OPINION

The Report of Independent Registered Public Accounting Firm includes an
explanatory paragraph to their audit opinions issued in connection with our 2005
and 2004 financial statements that states that we do not have significant cash
or other material assets to cover our operating costs. Our ability to obtain
additional funding will largely determine our ability to continue in business.
Accordingly, there is substantial doubt about our ability to continue as a going
concern. Our consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.

We can make no assurance that we will be able to successfully develop,
manufacturer and sell commercial products on a broad basis. While attempting to
make this transition, we will be subject to all the risks inherent in a growing
venture, including, but not limited to, the need to develop and manufacture
reliable and effective products, develop marketing expertise and expand our
sales force.

FACTORS AFFECTING KRONOS' BUSINESS AND PROSPECTS

We are subject to various risks which may have a material adverse effect on our
business, financial condition and results of operations, and may result in a
decline in our stock price. Certain risks are discussed below:

We have a limited operating history with significant losses and expect losses to
continue for the foreseeable future.

We have only recently begun implementing our plan to prioritize and concentrate
our management and financial resources to fully capitalize on our investment in
Kronos Air Technologies and have yet to establish any history of profitable
operations. We incurred a net loss of $2.6 million for the nine months ended
March 31, 2006. We incurred a net loss of $7.1 million for the fiscal year ended
June 30, 2005. As a result, at March 31, 2006 and June 30, 2005, we had an
accumulated deficit of $29.7 million and $27.1 million, respectively. Our
revenues and cash flows from operations have not been sufficient to sustain our
operations. We have sustained our operations through the issuance of our common
stock and the incurrence of debt. We expect that our revenues and cash flows
from operations may not be sufficient to sustain our operations for the
foreseeable future. Our profitability will require the successful
commercialization of our Kronos technologies. No assurances can be given that we
will be able to successfully commercialize our Kronos technologies or that we
will ever be profitable.

We will require significant additional financing to sustain our operations and
without it we will not be able to continue operations.

At March 31, 2006 and June 30, 2005, we had working capital deficits of $3.0
million and $3.6 million, respectively. The Report of Independent Registered
Public Accounting Firm for the year ended June 30, 2005, includes an explanatory
paragraph to their audit opinion stating that our recurring losses from
operations and working capital deficiency raise substantial doubt about our
ability to continue as a going concern. For the nine months ended March 31, 2006
and the fiscal year ended June 30, 2005, we had an operating cash flow deficit
of $2.6 million and $1.8 million, respectively. We currently do not have
sufficient financial resources to fund our operations or pay certain existing
obligations or those of our subsidiary. Therefore, we need substantial
additional funds to continue these operations and pay certain existing
obligations.

<PAGE>

If sufficient financing from HoMedics and /or Cornell Capital Partners were to
be unavailable and if we are unable to commercialize and sell our products or
technologies, we will need to secure another source of funding in order to
satisfy our working capital needs. Even if we are able to access the funds
available under the HoMedics senior debt agreement and / or the Cornell Capital
Standby Equity Distribution Agreement, we may still need additional capital to
fully implement our business, operating and development plans. At March 31, 2006
and June 30, 2005, we had a cash balance of $469,320 and $1,554,906,
respectively. Should the financing we require to sustain our working capital
needs be unavailable, or prohibitively expensive when we require it, we would be
forced to curtail our business operations.

Existing stockholders will experience significant dilution from our sale of
shares under the Cornell Capital Standby Equity Distribution Agreement and any
other equity financing.

The sale of shares pursuant to our agreement with Cornell Capital Partners, the
exercise of HoMedics stock warrants or any other future equity financing
transaction will have a dilutive impact on our stockholders. As a result, our
net income per share could decrease in future periods, and the market price of
our common stock could decline. In addition, the lower our stock price is, the
more shares of common stock we will have to issue under the Standby Equity
Distribution Agreement. If our stock price is lower, then our existing
stockholders would experience greater dilution. We cannot predict the actual
number of shares of common stock that will be issued pursuant to the Standby
Equity Distribution Agreement or any other future equity financing transaction,
in part, because the purchase price of the shares will fluctuate based on
prevailing market conditions and we do not know the exact amount of funds we
will need.

Competition in the market for air movement and purification devices may result
in the failure of the Kronos products to achieve market acceptance.

Kronos presently faces competition from other companies that are developing or
that currently sell air movement and purification devices. Many of these
competitors have substantially greater financial, research and development,
manufacturing, and sales and marketing resources than we do. Many of the
products sold by Kronos' competitors already have brand recognition and
established positions in the markets that we have targeted for penetration. In
the event that the Kronos products do not favorably compete with the products
sold by our competitors, we would be forced to curtail our business operations.

Our failure to enforce protection of our intellectual property would have a
material adverse effect on our business.

A significant part of our success depends in part on our ability to obtain and
defend our intellectual property, including patent protection for our products
and processes, preserve our trade secrets, defend and enforce our rights against
infringement and operate without infringing the proprietary rights of third
parties, both in the United States and in other countries. Our limited amount of
capital impedes our current ability to protect and defend our intellectual
property.

The validity and breadth of our intellectual property claims in ion wind
generation and electrostatic fluid acceleration and control technology involve
complex legal and factual questions and, therefore, may be highly uncertain.
Despite our efforts to protect our intellectual proprietary rights, existing
copyright, trademark and trade secret laws afford only limited protection.

Our industry is characterized by frequent intellectual property litigation based
on allegations of infringement of intellectual property rights. Although we are
not aware of any intellectual property claims against us, we may be a party to
litigation in the future.

Possible future impairment of intangible assets would have a material adverse
effect on our financial condition.

Our net intangible assets of approximately $2.0 million as of March 31, 2006
consist principally of purchased patent technology and marketing intangibles,
which relate to the acquisition of Kronos Air Technologies, Inc. in March 2000
and to the acquisition of license rights to fuel cell, computer and
microprocessor applications of the Kronos technology not included in the
original acquisition of Kronos Air Technologies, Inc. in May 2003. Intangible
assets comprise 78% of our total assets as of March 31, 2006. Intangible assets
are subject to periodic review and consideration for potential impairment of
value. Among the factors that could give rise to impairment include a
significant adverse change in legal factors or in the business climate, an
adverse action or assessment by a regulator, unanticipated competition, a loss
of key personnel, and projections or forecasts that demonstrate continuing
losses associated with these assets. In the case of our intangible assets,
specific factors that could give rise to impairment would be, but are not
limited to, an inability to obtain patents, the untimely death or other loss of
Dr. Igor Krichtafovitch, the lead inventor of the Kronos technology and Kronos
Air Technologies Chief Technology Officer, or the ability to create a customer
base for the sale or licensing of the Kronos technology. Should an impairment
occur, we would be required to recognize it in our financial statements. A
write-down of these intangible assets could have a material adverse impact on
our total assets, net worth and results of operations.

<PAGE>

Our common stock is deemed to be "Penny Stock," subject to special requirements
and conditions and may not be a suitable investment.

Our common stock is deemed to be "penny stock" as that term is defined in Rule
3a51-1 promulgated under the Securities Exchange Act of 1934. Penny stocks are
stocks:

     -    With a price of less than $5.00 per share;
     -    That are not traded on a "recognized" national exchange;
     -    Whose prices are not quoted on the Nasdaq  automated  quotation system
          (Nasdaq  listed  stock  must still have a price of not less than $5.00
          per share); or
     -    In issuers  with net  tangible  assets less than $2.0  million (if the
          issuer has been in  continuous  operation for at least three years) or
          $5.0 million (if in  continuous  operation for less than three years),
          or with average  revenues of less than $6.0 million for the last three
          years.

Broker/dealers dealing in penny stocks are required to provide potential
investors with a document disclosing the risks of penny stocks. Moreover,
broker/dealers are required to determine whether an investment in a penny stock
is a suitable investment for a prospective investor. These requirements may
reduce the potential market for our common stock by reducing the number of
potential investors. This may make it more difficult for investors in our common
stock to resell shares to third parties or to otherwise dispose of them. This
could cause our stock price to decline.

We rely on management and research personnel, the loss of whose services could
have a material adverse effect upon our business.

We rely principally upon the services of our senior executive management, and
certain key employees, including the Kronos research team, the loss of whose
services could have a material adverse effect upon our business and prospects.
Competition for appropriately qualified personnel is intense. Our ability to
attract and retain highly qualified senior management and technical research and
development personnel are believed to be an important element of our future
success. Our failure to attract and retain such personnel may, among other
things, limit the rate at which we can expand operations and achieve
profitability. There can be no assurance that we will be able to attract and
retain senior management and key employees having competency in those
substantive areas deemed important to the successful implementation of our plans
to fully capitalize on our investment in the Kronos technology, and the
inability to do so or any difficulties encountered by management in establishing
effective working relationships among them may adversely affect our business and
prospects. Currently, we do not carry key person life insurance for any of our
executive management, or key employees.

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures. As of the end of the period
covered by this report, the Company carried out an evaluation, under the
supervision and with the participation of the Company's Principal Executive
Officer and Principal Financial Officer of the effectiveness of the design and
operation of the Company's disclosure controls and procedures. The Company's
disclosure controls and procedures are designed to provide a reasonable level of
assurance of achieving the Company's disclosure control objectives. The
Company's Principal Executive Officer and Principal Financial Officer have
concluded that the Company's disclosure controls and procedures are, in fact,
effective at this reasonable assurance level as of the period covered. In
addition, the Company reviewed its internal controls, and there have been no
significant changes in its internal controls or in other factors that could
significantly affect those controls subsequent to the date of evaluation or from
the end of the reporting period to the date of this Form 10-QSB.

Changes in Internal Controls. In connection with the evaluation of the Company's
internal controls during the Company's first fiscal quarter ended March 31,
2006, the Company's Principal Executive Officer and Principal Financial Officer
have determined that there are no changes to the Company's internal controls
over financial reporting that has materially affected, or is reasonably likely
to materially effect, the Company's internal controls over financial reporting
during the fiscal quarter ended March 31, 2006, or subsequent to the date of
their last evaluation, or from the end of the reporting period to the date of
this Form 10-QSB.

<PAGE>

                                     PART II

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

During the nine months ended March 31, 2006, we issued 50,177,071 shares of
Kronos common stock to Cornell Capital Partners under our Standby Equity
Distribution Agreement. The proceeds from the issuance of these shares were used
to repay $1,760,000 of debt and to increase the Company's cash reserves by
$1,100,000.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. EXHIBITS


<TABLE>
<CAPTION>
EXHIBIT NO.     DESCRIPTION                                  LOCATION
-------------------------------------------------------------------------------------------------
<S>                                                          <C>
 2.1            Articles of Merger for Technology            Incorporated by reference to
                Selection, Inc. with the Nevada              Exhibit 2.1 to the Registrant's
                Secretary of State                           Registration Statement on Form
                                                             S-1 filed on August 7, 2001 (the
                                                             "Registration Statement")

 3.1            Articles of Incorporation                    Incorporated by reference to
                                                             Exhibit 3.1 to the Registration
                                                             Statement on Form S-1 filed on
                                                             August 7, 2001

 3.2            Bylaws                                       Incorporated by reference to
                                                             Exhibit 3.2 to the Registration
                                                             Statement on Form S-1 filed on
                                                             August 7, 2001

 4.1            2001 Stock Option Plan                       Incorporated by reference to
                                                             Exhibit 4.1 to
                                                             Registrant's Form
                                                             10-Q for the
                                                             quarterly period
                                                             ended March 31,
                                                             2002 filed on May
                                                             15, 2002

10.21           Indemnification Agreement, dated May 1,      Incorporated by reference to
                2001, by and between TSET, Inc. and          Exhibit 10.38 to the
                Daniel R. Dwight                             Registration Statement on Form
                                                             S-1 filed on August 7, 2001

10.22           Indemnification Agreement, dated May 1,      Incorporated by reference to
                2001, by and between TSET, Inc. and          Exhibit 10.39 to the
                Richard F. Tusing                            Registration Statement on Form
                                                             S-1 filed on August 7, 2001

10.23           Employment Agreement, effective              Incorporated by reference to
                February 11, 2001 by and between             Exhibit 10.55 to the Registrant's
                TSET, Inc. and Daniel R. Dwight              Form 10-Q for the quarterly period
                                                             ended March 31, 2002 filed on
                                                             May 15, 2002

<PAGE>

10.24           Master Loan and Investment                   Incorporated by reference to
                Agreement, dated May 9, 2003,                the Registrant's 8-K filed on
                by and among Kronos Advanced                 May 15, 2003
                Technologies, Inc., Kronos Air
                Technologies, Inc. and FKA
                Distributing Co. d/b/a HoMedics,
                Inc., a Michigan corporation
                ("HoMedics")

10.25           Secured Promissory Note, dated               Incorporated by reference to
                May 9, 2003, in the principal                Exhibit 99.2 to the Registrant's
                amount of $2,400,000 payable to              8-K filed on May 15, 2003
                HoMedics

10.26           Secured Promissory Note, dated               Incorporated by reference to
                May 9, 2003, in the principal                Exhibit 99.4 to the Registrant's
                amount of $1,000,000 payable to              8-K filed on May 15, 2003
                HoMedics

10.27           Security Agreement dated May 9,              Incorporated by reference to
                2003, by and among Kronos Air                Exhibit 99.4 to the Registrant's
                Technologies, Inc. and HoMedics              8-K filed on May 15, 2003

10.28           Registration Rights Agreement,               Incorporated by reference to
                dated May 9, 2003, by and between            Exhibit 99.5 to the Registrant's
                Kronos and HoMedics                          8-K filed on May 15, 2003


10.29           Warrant No. 1 dated May 9, 2003,             Incorporated by reference to
                issued to HoMedics                           Exhibit 99.7 to the Registrant's
                                                             8-K filed on May 15, 2003

10.30           Warrant No. 2 dated May 9, 2003,             Incorporated by reference to
                issued to HoMedics                           Exhibit 99.7 to the Registrant's
                                                             8-K filed on May 15, 2003
                                                             2002

10.31           Consulting Agreement effective               Incorporated by reference to
                October 31, 2003, by and among Kronos        Exhibit 10.67 to the Registrant's
                Advanced Technologies, Inc.,                 Form 10-Q for the quarterly period
                Steven G. Martin and Joshua B. on            ended March 31, 2003 filed on
                Scheinfeld                                   February 17, 2004

10.32           Promissory Note by and among Kronos          Incorporated by reference to
                Advanced Technologies, Inc., and             Exhibit 10.67 to the Registrant's
                Richard A. Papworth                          Form 10-Q for the quarterly period
                                                             ended March 31, 2004 filed on
                                                             May 17, 2004

10.33           Promissory Note by and among Kronos          Incorporated by reference to
                Advanced Technologies, Inc., and             Exhibit 10.67 to the Registrant's
                Daniel R. Dwight                             Form 10-Q for the quarterly period
                                                             ended March 31, 2004 filed on
                                                             May 17, 2004

<PAGE>

10.34           Promissory Note by and among Kronos          Incorporated by reference to
                Advanced Technologies, Inc., and             Exhibit 10.67 to the Registrant's
                Richard F. Tusing                            Form 10-Q for the quarterly period
                                                             ended March 31, 2004 filed on
                                                             May 17, 2004

10.35           Promissory Note by and among Kronos          Incorporated by reference to
                Advanced Technologies, Inc., and             Exhibit 10.67 to the Registrant's
                Igor Krichtafovitch                          Form 10-Q for the quarterly period
                                                             ended March 31, 2004 filed on
                                                             May 17, 2004

10.36           Promissory Note by and among Kronos          Incorporated by reference to
                Advanced Technologies, Inc., and             Exhibit 10.67 to the Registrant's
                J. Alexander Chriss                          Form 10-Q for the quarterly period
                                                             ended March 31, 2004 filed on
                                                             May 17, 2004

10.37           Securities Purchase Agreement, dated         Incorporated by reference to
                October 15, 2004, by and between Kronos      Exhibit 99.5 to the Registrant's
                Advanced Technologies, Inc. and Cornell      Form 8-K filed on November 12, 2004
                Capital Partners, LP


10.38           Investor Registration Rights Agreement,      Incorporated by reference to
                dated October 15, 2004, by and between       Exhibit 99.6 to the Registrant's
                Kronos Advanced Technologies, Inc. and       Form 8-K filed on November 12, 2004
                Cornell Capital Partners, LP

10.39           Escrow Agreement, dated October 15, 2004,    Incorporated by reference to
                by and between Kronos Advanced               Exhibit 99.7 to the Registrant's
                Technologies, Inc. and Cornell Capital       Form 8-K filed on November 12, 2004
                Partners, LP

10.40           First Amendment to Master Loan and           Incorporated by reference to
                Investment Agreement, dated October 25,      Exhibit 99.9 to the
                Registrant's 2004, by and among Kronos       Form 8-K filed on November 12, 2004
                Advanced Technologies, Inc., f/k/a TSET,
                Inc., a Nevada corporation, Kronos Air
                Technologies, Inc., a Nevada corporation
                and FKA Distributing Co. d/b/a HoMedics,
                Inc., a Michigan corporation

10.41           Secured Promissory Note, dated October       Incorporated by reference to
                25, 2004, payable to FKA Distributing        Exhibit 99.10 to the Registrant's
                Co., d/b/a HoMedics, Inc., a Michigan        Form 8-K filed on November 12, 2004
                corporation, in the principal amount of
                $925,000

10.42           Amended and Restated Warrant No. 1,          Incorporated by reference to
                dated October 25, 2004, issued to FKA        Exhibit 99.11 to the Registrant's
                Distributing Co. d/b/a HoMedics, Inc.        Form 8-K filed on November 12, 2004

10.43           Amended and Restated Warrant No. 2,          Incorporated by reference to
                dated October 25, 2004, issued to FKA        Exhibit 99.12 to the Registrant's
                Distributing Co. d/b/a HoMedics, Inc.        Form 8-K filed on November 12, 2004

10.44           Warrant No. 3, dated October 25, 2004,       Incorporated by reference to
                issued to FKA Distributing Co. d/b/a         Exhibit 99.13 to the Registrant's
                HoMedics, Inc.                               Form 8-K filed on November 12, 2004

<PAGE>

10.45           Amended and Restated Registration Rights     Incorporated by reference to
                Agreement, dated October 25, 2004, by        Exhibit 99.14 to the Registrant's
                And between Kronos Advanced                  Form 8-K filed on November 12, 2004
                Technologies Inc., a Nevada corporation
                and FKA Distributing Co. d/b/a HoMedics,
                a Michigan corporation

10.46           Termination Agreement dated March 28,        Incorporated by reference to Exhibit
                2005, by and between Kronos Advanced         10.63 to the Registrant's Form SB-2
                Technologies, Inc. and Cornell Capital       filed on April 19, 2005
                Partners, LP

10.47           Standby Equity Distribution Agreement,       Incorporated by reference to Exhibit
                dated April 13, 2005, by and between         10.64 to the Registrant's Form SB-2
                Kronos Advanced Technologies, Inc. and       filed on April 19, 2005
                Cornell Capital Partners, LP

10.48           Registration Rights Agreement, dated         Incorporated by reference to Exhibit
                April 13, 2005, by and between Kronos        10.65 to the Registrant's Form SB-2
                Advanced Technologies, Inc. and Cornell      filed on April 19, 2005
                Capital Partners, LP

10.49           Escrow Agreement, dated April 13, 2005,      Incorporated by reference to Exhibit
                by and between Kronos Advanced               10.66 to the Registrant's Form SB-2
                Technologies, Inc. and Cornell Capital       filed on April 19, 2005
                Partners, LP

10.50           Placement Agent Agreement, dated April       Incorporated by reference to Exhibit
                13, 2005, by and between Kronos Advanced     10.67 to the Registrant's Form SB-2
                Technologies, Inc. and Cornell Capital       filed on April 19, 2005
                Partners, LP


10.51           Form of Equity-Back Promissory Note in       Incorporated by reference to Exhibit
                the principal amount of $2,000,000 dated     10.68 to the Registrant's Form SB-2
                March 7, 2005 between Kronos Advanced        filed on April 19, 2005
                Technologies, Inc. and Cornell Capital
                Partners, LP

10.52           Form of Equity-Back Promissory Note in       Incorporated by reference to Exhibit
                the principal amount of $2,000,000 dated     10.59 to the Registrant's Form 10-KSB
                June 22, 2005 between Kronos Advanced        filed on September 28, 2005
                Technologies, Inc. and Cornell Capital
                Partners, LP
</TABLE>

<PAGE>

EXHIBIT NO.     DESCRIPTION                                  LOCATION
--------------------------------------------------------------------------------
31.1            Certification of Chief Executive              Provided herewith
                Officer pursuant to 15 U.S.C.
                Section 7241, as adopted pursuant
                to Section 302 of the Sarbanes-Oxley
                Act of 2002

31.2            Certification of Principal Financial          Provided herewith
                Officer pursuant to U.S.C. Section
                7241, as adopted pursuant to Section
                302 of the Sarbanes-Oxley Act of 2002

32.1            Certification by Chief Executive Officer      Provided herewith
                pursuant to 18 U.S.C. Section 1350, as
                adopted pursuant to Section 906 of the
                Sarbanes-Oxley Act of 2002

32.2            Certification by Princiapl Financial          Provided herewith
                Officer pursuant to 18 U.S.C. Section
                1350, as adopted pursuant to Section
                906 of the Sarbanes-Oxley Act of 2002

                                   Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.





DATED:   May 15, 2006                  KRONOS ADVANCED TECHNOLOGIES, INC.

                                   By: /s/ DANIEL R. DWIGHT
                                           ----------------------
                                           Daniel R. Dwight
                                           President and Chief Executive Officer


                                   By: /s/ DANIEL R. DWIGHT
                                           ------------------------
                                           Daniel R. Dwight
                                           Acting Chief Financial Officer